{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p1", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and TFIIIC63) of human [E2]TFIIIC[/E2] and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "pm0120026", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d1.s2_HPRD50.d1.s2.p0", "text": "It was previously shown that the N-terminus of CCR2 is critical for binding MCP-1", "text_with_entity_marker": "It was previously shown that the N-terminus of [E1]CCR2[/E1] is critical for binding [E2]MCP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CCR2", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "pm0111607", "entity_1_type_id": 4, "entity_2": "MCP-1", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "pm0111607||pm0117207||pm0124628", "entity_2_type_id": 5}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s2_HPRD50.d2.s2.p0", "text": "This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the LH beta or FSH beta subunits are different", "text_with_entity_marker": "This is relevant for the case of LH and FSH, because both are synthesized in the same cell (i.e., pituitary gonadotrophs) and several of the alpha subunit sequences required for association with either the [E1]LH beta[/E1] or [E2]FSH beta[/E2] subunits are different", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LH beta", "entity_1_idx": [[206, 213]], "entity_1_idx_in_text_with_entity_marker": [210, 217], "entity_1_type": "pm0117290", "entity_1_type_id": 10, "entity_2": "FSH beta", "entity_2_idx": [[217, 225]], "entity_2_idx_in_text_with_entity_marker": [230, 238], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d4.s1_HPRD50.d4.s1.p0", "text": "Immobilized FGFR4 also bound FGF-8 besides FGF-1 and FGF-2", "text_with_entity_marker": "Immobilized [E1]FGFR4[/E1] also bound [E2]FGF-8[/E2] besides FGF-1 and FGF-2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "FGFR4", "entity_1_idx": [[12, 17]], "entity_1_idx_in_text_with_entity_marker": [16, 21], "entity_1_type": "pm0119069", "entity_1_type_id": 18, "entity_2": "FGF-8", "entity_2_idx": [[29, 34]], "entity_2_idx_in_text_with_entity_marker": [42, 47], "entity_2_type": "pm0118903", "entity_2_type_id": 19}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s0_HPRD50.d7.s0.p0", "text": "Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2", "text_with_entity_marker": "Suppression of rat thromboxane synthase gene transcription by [E1]peroxisome proliferator-activated receptor gamma[/E1] in macrophages via an interaction with [E2]NRF2[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "peroxisome proliferator-activated receptor gamma", "entity_1_idx": [[62, 110]], "entity_1_idx_in_text_with_entity_marker": [66, 114], "entity_1_type": "pm0103183", "entity_1_type_id": 26, "entity_2": "NRF2", "entity_2_idx": [[150, 154]], "entity_2_idx_in_text_with_entity_marker": [163, 167], "entity_2_type": "pm0105918||pm0123857", "entity_2_type_id": 27}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s3_HPRD50.d10.s3.p0", "text": "Finally, sialoadhesin bound different glycoforms of CD43 expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "text_with_entity_marker": "Finally, [E1]sialoadhesin[/E1] bound different glycoforms of [E2]CD43[/E2] expressed in Chinese hamster ovary cells, including unbranched (core 1) and branched (core 2) O:-linked glycans, that are normally found on CD43 in resting and activated T cells, respectively", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "sialoadhesin", "entity_1_idx": [[9, 21]], "entity_1_idx_in_text_with_entity_marker": [13, 25], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "CD43", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s0_HPRD50.d12.s0.p0", "text": "AP180 binds to the C-terminal SH2 domain of phospholipase C-gamma1 and inhibits its enzymatic activity", "text_with_entity_marker": "[E1]AP180[/E1] binds to the C-terminal SH2 domain of [E2]phospholipase C-gamma1[/E2] and inhibits its enzymatic activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AP180", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0106306", "entity_1_type_id": 41, "entity_2": "phospholipase C-gamma1", "entity_2_idx": [[44, 66]], "entity_2_idx_in_text_with_entity_marker": [57, 79], "entity_2_type": "pm0126499", "entity_2_type_id": 42}], "directed": false, "reverse": false}
{"id": "HPRD50.d12.s1_HPRD50.d12.s1.p2", "text": "In this report, we demonstrate the stable association of PLCgamma1 with AP180 in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of PLCgamma1, but also inhibits its enzymatic activity in a dose-dependent manner", "text_with_entity_marker": "In this report, we demonstrate the stable association of PLCgamma1 with [E1]AP180[/E1] in a clathrin-coated vesicle complex, which not only binds to the carboxyl-terminal SH2 domain of [E2]PLCgamma1[/E2], but also inhibits its enzymatic activity in a dose-dependent manner", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "AP180", "entity_1_idx": [[72, 77]], "entity_1_idx_in_text_with_entity_marker": [76, 81], "entity_1_type": "pm0106306", "entity_1_type_id": 41, "entity_2": "PLCgamma1", "entity_2_idx": [[176, 185]], "entity_2_idx_in_text_with_entity_marker": [189, 198], "entity_2_type": "pm0126499", "entity_2_type_id": 42}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s0_HPRD50.d13.s0.p0", "text": "Here we demonstrate colocalization and direct interaction between CLIP-170 and LIS1", "text_with_entity_marker": "Here we demonstrate colocalization and direct interaction between [E1]CLIP-170[/E1] and [E2]LIS1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CLIP-170", "entity_1_idx": [[66, 74]], "entity_1_idx_in_text_with_entity_marker": [70, 78], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[79, 83]], "entity_2_idx_in_text_with_entity_marker": [92, 96], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p0", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "[E1]GADD45b[/E1] and [E2]GADD45g[/E2] are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GADD45b", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "GADD45g", "entity_2_idx": [[12, 19]], "entity_2_idx_in_text_with_entity_marker": [25, 32], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p1", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of [E1]Cdk1[/E1]/cyclinB1 kinase activity by Gadd45b and [E2]Gadd45a[/E2] was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Cdk1", "entity_1_idx": [[14, 18]], "entity_1_idx_in_text_with_entity_marker": [18, 22], "entity_1_type": "pm0113152", "entity_1_type_id": 53, "entity_2": "Gadd45a", "entity_2_idx": [[59, 66]], "entity_2_idx_in_text_with_entity_marker": [72, 79], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p1", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of [E1]p300[/E1] binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, [E2]MEF2A[/E2] and p300 form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "p300", "entity_1_idx": [[56, 60]], "entity_1_idx_in_text_with_entity_marker": [60, 64], "entity_1_type": "pm0126787", "entity_1_type_id": 65, "entity_2": "MEF2A", "entity_2_idx": [[158, 163]], "entity_2_idx_in_text_with_entity_marker": [171, 176], "entity_2_type": "pm0122391", "entity_2_type_id": 67}], "directed": false, "reverse": false}
{"id": "HPRD50.d21.s0_HPRD50.d21.s0.p0", "text": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system", "text_with_entity_marker": "In the present study, we observed evidence of cross-talk between the cannabinoid receptor [E1]CB1[/E1] and the [E2]orexin 1 receptor[/E2] (OX1R) using a heterologous system", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CB1", "entity_1_idx": [[90, 93]], "entity_1_idx_in_text_with_entity_marker": [94, 97], "entity_1_type": "pm0109721", "entity_1_type_id": 71, "entity_2": "orexin 1 receptor", "entity_2_idx": [[102, 119]], "entity_2_idx_in_text_with_entity_marker": [115, 132], "entity_2_type": "pm0111533", "entity_2_type_id": 72}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s2_HPRD50.d22.s2.p0", "text": "In addition, GC-GAP contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length Nck in vitro", "text_with_entity_marker": "In addition, [E1]GC-GAP[/E1] contains several classic proline-rich motifs, and it interacts with the first SH3 domain of Crk and full-length [E2]Nck[/E2] in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[13, 19]], "entity_1_idx_in_text_with_entity_marker": [17, 23], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Nck", "entity_2_idx": [[132, 135]], "entity_2_idx_in_text_with_entity_marker": [145, 148], "entity_2_type": "pm0121922", "entity_2_type_id": 79}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p5", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of [E1]GC-GAP[/E1] under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "GC-GAP", "entity_1_idx": [[118, 124]], "entity_1_idx_in_text_with_entity_marker": [122, 128], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p2", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that Plk1 phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p6", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and [E1]NudC[/E1], show that Plk1 phosphorylates [E2]NudC[/E2] at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[91, 95]], "entity_2_idx_in_text_with_entity_marker": [104, 108], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p1", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of [E1]NudC[/E1] by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by [E2]NudC[/E2] with mutations in the Plk1 phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[217, 221]], "entity_2_idx_in_text_with_entity_marker": [230, 234], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s2_HPRD50.d23.s2.p4", "text": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type NudC, but not by NudC with mutations in the Plk1 phosphorylation sites", "text_with_entity_marker": "Downregulation of NudC by RNA interference results in multiple mitotic defects, including multinucleation and cells arrested at the midbody stage, which are rescued by ectopic expression of wild-type [E1]NudC[/E1], but not by NudC with mutations in the [E2]Plk1[/E2] phosphorylation sites", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[200, 204]], "entity_1_idx_in_text_with_entity_marker": [204, 208], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "Plk1", "entity_2_idx": [[244, 248]], "entity_2_idx_in_text_with_entity_marker": [257, 261], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s3_HPRD50.d23.s3.p0", "text": "These results suggest that Plk1 phosphorylation of NudC may influence cytokinesis", "text_with_entity_marker": "These results suggest that [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] may influence cytokinesis", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[51, 55]], "entity_2_idx_in_text_with_entity_marker": [64, 68], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s1_HPRD50.d25.s1.p1", "text": "BACKGROUND: Both androgen receptor (AR) and orphan receptor TR2 (TR2) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "text_with_entity_marker": "BACKGROUND: Both [E1]androgen receptor[/E1] (AR) and orphan receptor TR2 ([E2]TR2[/E2]) belong to the steroid nuclear receptor superfamily and are expressed in prostate cancer tissue and cell lines", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "androgen receptor", "entity_1_idx": [[17, 34]], "entity_1_idx_in_text_with_entity_marker": [21, 38], "entity_1_type": "pm0125088", "entity_1_type_id": 91, "entity_2": "TR2", "entity_2_idx": [[65, 68]], "entity_2_idx_in_text_with_entity_marker": [78, 81], "entity_2_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_2_type_id": 90}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p2", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "[E1]TBP-1[/E1] associates with the beta-domain of pVHL and complexes with pVHL and [E2]Hif1 alpha[/E2] in vivo", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TBP-1", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[74, 84]], "entity_2_idx_in_text_with_entity_marker": [87, 97], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p1", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of [E1]TBP-1[/E1] promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of [E2]TBP-1[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "TBP-1", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d27.s0_HPRD50.d27.s0.p5", "text": "Pinin/DRS/memA interacts with SRp75, SRm300 and SRrp130 in corneal epithelial cells", "text_with_entity_marker": "Pinin/DRS/memA interacts with [E1]SRp75[/E1], [E2]SRm300[/E2] and SRrp130 in corneal epithelial cells", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRp75", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "pm0111657", "entity_1_type_id": 97, "entity_2": "SRm300", "entity_2_idx": [[37, 43]], "entity_2_idx_in_text_with_entity_marker": [50, 56], "entity_2_type": "pm0117461", "entity_2_type_id": 98}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s0_HPRD50.d28.s0.p2", "text": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1)", "text_with_entity_marker": "We report that MSH2 (MutS homolog 2) protein interacts with the ATR (ATM- and Rad3-related) kinase to form a signaling module and regulate the phosphorylation of [E1]Chk1[/E1] and [E2]SMC1[/E2] (structure maintenance of chromosome 1)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Chk1", "entity_1_idx": [[162, 166]], "entity_1_idx_in_text_with_entity_marker": [166, 170], "entity_1_type": "pm0113524", "entity_1_type_id": 100, "entity_2": "SMC1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s3_HPRD50.d28.s3.p2", "text": "In addition, both MSH2 and Rad17 are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of SMC1 is required for cellular survival", "text_with_entity_marker": "In addition, both MSH2 and [E1]Rad17[/E1] are required for the activation of the S-phase checkpoint to suppress DNA synthesis in response to MNNG, and phosphorylation of [E2]SMC1[/E2] is required for cellular survival", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Rad17", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "pm0117336", "entity_1_type_id": 102, "entity_2": "SMC1", "entity_2_idx": [[161, 165]], "entity_2_idx_in_text_with_entity_marker": [174, 178], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p1", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that [E1]Dnmt3a[/E1] interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases [E2]PIAS1[/E2] and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "PIAS1", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "pm0117395", "entity_2_type_id": 106}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s3_HPRD50.d29.s3.p2", "text": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b", "text_with_entity_marker": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases ([E1]HDAC1[/E1]/2), but not with another interaction partner, [E2]Dnmt3b[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "HDAC1", "entity_1_idx": [[96, 101]], "entity_1_idx_in_text_with_entity_marker": [100, 105], "entity_1_type": "pm0119729", "entity_1_type_id": 108, "entity_2": "Dnmt3b", "entity_2_idx": [[148, 154]], "entity_2_idx_in_text_with_entity_marker": [161, 167], "entity_2_type": "pm0126533", "entity_2_type_id": 109}], "directed": false, "reverse": false}
{"id": "HPRD50.d30.s0_HPRD50.d30.s0.p2", "text": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon (IFN) receptor complex and is rapidly activated during IFN alpha stimulation", "text_with_entity_marker": "The tyrosine kinase Tyk-2 is physically associated with the Type I interferon ([E1]IFN[/E1]) receptor complex and is rapidly activated during [E2]IFN alpha[/E2] stimulation", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "IFN", "entity_1_idx": [[79, 82]], "entity_1_idx_in_text_with_entity_marker": [83, 86], "entity_1_type": "pm0111853", "entity_1_type_id": 111, "entity_2": "IFN alpha", "entity_2_idx": [[133, 142]], "entity_2_idx_in_text_with_entity_marker": [146, 155], "entity_2_type": "pm0111853", "entity_2_type_id": 111}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s0_HPRD50.d31.s0.p0", "text": "Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation", "text_with_entity_marker": "[E1]Raf1[/E1] interaction with [E2]Cdc25[/E2] phosphatase ties mitogenic signal transduction to cell cycle activation", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Raf1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0117803", "entity_1_type_id": 112, "entity_2": "Cdc25", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "pm0106635||pm0109000", "entity_2_type_id": 113}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s3_HPRD50.d32.s3.p0", "text": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell (SMC)-derived PGs to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "text_with_entity_marker": "In the present investigation, the differential binding of previously characterized endothelial cell (EC)- and smooth muscle cell ([E1]SMC[/E1])-derived [E2]PGs[/E2] to A beta was examined to determine whether the accumulation of A beta in cerebrovascular amyloid deposits may be due to its interactions with perlecan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[130, 133]], "entity_1_idx_in_text_with_entity_marker": [134, 137], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PGs", "entity_2_idx": [[143, 146]], "entity_2_idx_in_text_with_entity_marker": [156, 159], "entity_2_type": "pm0108066", "entity_2_type_id": 121}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s5_HPRD50.d32.s5.p0", "text": "[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin", "text_with_entity_marker": "[35S]-Sulfate labeled proteoglycans ([E1]PGs[/E1]) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine [E2]serum albumin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "PGs", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "serum albumin", "entity_2_idx": [[253, 266]], "entity_2_idx_in_text_with_entity_marker": [266, 279], "entity_2_type": "pm0103143", "entity_2_type_id": 124}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p15", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d35.s0_HPRD50.d35.s0.p0", "text": "Assignment of Etfdh, Etfb, and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human", "text_with_entity_marker": "Assignment of [E1]Etfdh[/E1], [E2]Etfb[/E2], and Etfa to chromosomes 3, 7, and 13: the mouse homologs of genes responsible for glutaric acidemia type II in human", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Etfdh", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "pm0103481", "entity_1_type_id": 133, "entity_2": "Etfb", "entity_2_idx": [[21, 25]], "entity_2_idx_in_text_with_entity_marker": [34, 38], "entity_2_type": "pm0110405", "entity_2_type_id": 134}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p2", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for [E1]PTP-1C[/E1] regulates tyrosyl phosphorylation of [E2]CD22[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[78, 84]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d37.s0_HPRD50.d37.s0.p3", "text": "TFIID dimers formed through self-association of the TATA-binding polypeptide (TBP) subunit and could be immunoprecipitated with antibodies to TAF(II)250, the core subunit of TFIID", "text_with_entity_marker": "TFIID dimers formed through self-association of the TATA-binding polypeptide ([E1]TBP[/E1]) subunit and could be immunoprecipitated with antibodies to [E2]TAF(II)250[/E2], the core subunit of TFIID", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP", "entity_1_idx": [[78, 81]], "entity_1_idx_in_text_with_entity_marker": [82, 85], "entity_1_type": "pm0109127", "entity_1_type_id": 137, "entity_2": "TAF(II)250", "entity_2_idx": [[142, 152]], "entity_2_idx_in_text_with_entity_marker": [155, 165], "entity_2_type": "pm0108292", "entity_2_type_id": 138}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p4", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p7", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, [E2]loricrin[/E2], and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "loricrin", "entity_2_idx": [[265, 273]], "entity_2_idx_in_text_with_entity_marker": [278, 286], "entity_2_type": "pm0103809", "entity_2_type_id": 143}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p8", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p11", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, [E1]desmoplakin[/E1], elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "desmoplakin", "entity_1_idx": [[187, 198]], "entity_1_idx_in_text_with_entity_marker": [191, 202], "entity_1_type": "pm0110549", "entity_1_type_id": 141, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p2", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated SRcyp/[E1]CASP10[/E1], specifically interacts with the [E2]CTD[/E2] not only in vivo but also in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CASP10", "entity_1_idx": [[38, 44]], "entity_1_idx_in_text_with_entity_marker": [42, 48], "entity_1_type": "pm0122990", "entity_1_type_id": 145, "entity_2": "CTD", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0113359", "entity_2_type_id": 146}], "directed": false, "reverse": false}
{"id": "HPRD50.d40.s1_HPRD50.d40.s1.p0", "text": "These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1", "text_with_entity_marker": "These results suggest that the relative abundance of the two splice variants of [E1]E2-2[/E1] in brain could be an important determinant for the expression of [E2]FGF-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "E2-2", "entity_1_idx": [[80, 84]], "entity_1_idx_in_text_with_entity_marker": [84, 88], "entity_1_type": "pm0110165", "entity_1_type_id": 148, "entity_2": "FGF-1", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "pm0124654", "entity_2_type_id": 16}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s3_HPRD50.d42.s3.p0", "text": "TBP and TFIIA, however, were not able to interact with IkappaBbeta", "text_with_entity_marker": "TBP and [E1]TFIIA[/E1], however, were not able to interact with [E2]IkappaBbeta[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIA", "entity_1_idx": [[8, 13]], "entity_1_idx_in_text_with_entity_marker": [12, 17], "entity_1_type": "pm0112153||pm0118250", "entity_1_type_id": 154, "entity_2": "IkappaBbeta", "entity_2_idx": [[55, 66]], "entity_2_idx_in_text_with_entity_marker": [68, 79], "entity_2_type": "pm0122183", "entity_2_type_id": 152}], "directed": false, "reverse": false}
